This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck & Co. (MRK) Passes First Test on Allergy Drug

NEW YORK (TheStreet) -- Danish pharmaceutical company ALK announced it had received unanimous support from a U.S. Food and Drug Administration (FDA) advisory committee for oral drug Gratsek. The drug, designed to treat glass pollen allergies, is one developed as part of ALK's strategic partnership with Merck & Co. (MRK - Get Report), a marriage which will grant the latter license to market and sell the product in North American markets.

The FDA said the available data demonstrated Gratsek's efficacy and safety among patients aged five to 65, but recommended further studies related to its use among children aged 11 years and under.

"ALK welcomes the FDA Advisory Committee's conclusion, which represents another important step towards bringing this innovative new treatment to U.S. patients," ALK CEO Jens Bager said in a statement.

The FDA will review Merck's Biologic License Application for Gratsek, taking the advisory committee's opinion into consideration, and the drug's approval could be granted as early as the first half of 2014.

Must Read: Why Ciena (CIEN) Missed Revenue Plunging Shares

Merck shares were off 0.39% to $48.32 by market close. In post-market trading, the stock had regained 0.29% to $48.46.

--Written by Keris Alison Lahiff.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRK $49.38 0.00%
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs